With $100M, startup to bring Lilly-licensed drug into trials

Just about four months after launching publicly with $20 million in hand and a drug in-licensed from Eli Lilly & Co., Acrivon Therapeutics Inc. has brought in a whopping $100 million to move the drug through in-human trials.